Truncated Plasmodium berghei putative secreted ookinete protein 7 induces transmission-blocking immunity

doi:10.12140/j.issn.1000-7423.2019.05.003

Abstract

Abstract:

Objective To investigate the truncated Plasmodium berghei putative secreted ookinete protein 7 (PbPSOP7) induces transmission-blocking immunity determined by in vitro antibody blocking and mosquito feeding assays. Methods Recombinant PbPSOP7 protein (rPbPSOP7) was expressed in E. coli and the anti-rPbPSOP7 sera were obtained by immunizing BALB/c mice for three times with rPbPSOP7 formulated with Freund’s adjuvant. For in vitro test, P. berghei-infected mouse blood was obtained from a mouse infected with 5 × 10⁶ P. berghei for three days, then co-incubated with mouse anti-rPbPSOP7 sera at 1 : 5, 1 : 10 and 1 : 50 dilutions. Mouse anti- a non-relevant His-tag protein serum at the same dilutions was used as control. The inhibition on the exflagellation of Plasmodium gametocytes was observed 15 min after the culture and the inhibition on the ookinete development was observed 24 hours after incubation. For mosquito feeding experiment, 5 mice were each immunized with 50 μg of rPbPSOP7 formulated with Freund’s adjuvant for three times, then infected with 5 × 10⁶ P. berghei by intraperitoneal injection 10 days after the last immunization. Three days post-infection, the mice were fed by at least 50 female anopheles mosquitoes. The mosquitoes were dissected 10 days after the blood feeding, the infection rate and the reduced number of oocysts in each infected mosquito were calculated compared with mosquitoes fed with mice immunized with His-tag control protein. The feeding experiment was repeated three times. Results When incubated with mouse anti-rPbPSOP7 sera at the 1 : 5, 1 : 10 or 1 : 50 dilutions for 15 min, the exflagellation of gametocytes was decreased by 22.0%, 8.0% and 2.0% compared to Plasmodium incubated with sera from mice immunized with His-tag protein(P > 0.05). After incubated with mouse anti-rPbPSOP7 sera for 24 hours, the significant inhibition of ookinete development was observed in the culture with different dilutions of the antisera. The development of ookinete was reduced by 69.2%, 56.4% and 48.6% when incubated with anti-rPbPSOP7 sera at 1 : 5, 1 : 10 and 1 : 50 dilutions, respectively, compared with control sera group (P < 0.01). Three independent mosquito feeding experiments showed that, compared with the control group, the development of oocysts in the midgut of mosquitoes in immunized group was significantly decreased from 87.1 ± 69.3, 96.4 ± 82.9 and 85.3 ± 69.1 to 31.1 ± 34.9, 30.2 ± 32.3 and 29.1 ± 35.1, respectively. Anti-rPbPSOP7 sera reduced the development of oocyst by 64.2%, 68.6% and 65.8% in three independent feeding experiments (P < 0.01). The infection rates of P. berghei in mosquitoes decreased from 96.4% (27/28), 89.3% (25/28) and 89.3% (25/28) to 78.6% (22/28), 78.6% (22/28) and 75.0% (21/28) in three experiments, with 17.8%, 10.7% and 14.3% reduction (P > 0.05). Conclusion Immunization of rPbPSOP7 induced transmission-blocking immunity characterized by reduced development of P. berghei ookinate and oocyst in mosquitoes, indicating that PbPSOP7 is a potential malaria transmission-blocking vaccine candidate.

Key words: Plasmodium berghei, Transmission-blocking vaccines, Candidate antigen, Putative secreted ookinete protein 7

CLC Number:

R531.3

Wen-qi ZHENG, Jun-rui WANG, Hua WANG, Fei LIU, En-jie LUO, Ya-ming CAO, Yan-qiu HAN. Truncated Plasmodium berghei putative secreted ookinete protein 7 induces transmission-blocking immunity[J]. CHINESE JOURNAL OF PARASITOLOGY AND PARASITIC DISEASES, 2019, 37(5): 520-525.

Figures/Tables 4

References 19

[1]	World Health Organization: World malaria report 2018[M]. Geneva: WHO Press, 2018: 14-15.
[2]	雷正龙, 王立英. 全国重点寄生虫病防治形势与主要任务[J]. 中国寄生虫学与寄生虫病杂志, 2012, 30(1): 1-5.
[3]	张丽, 丰俊, 张少森, 等. 2017年全国消除疟疾进展及疫情特征分析[J].中国寄生虫学与寄生虫病杂志, 2018, 36(3): 201-209.
[4]	刘怀鄂, 苏品璨, 陈熙, 等. 常用抗间日疟药物抗药性机制研究进展[J]. 中国病原生物学杂志, 2018, 13(9): 1049-1051, 1053.
[5]	牟畇珊, 李璐杰, 吴银娟, 等. 疟原虫青蒿素耐药分子机制探索[J]. 中国寄生虫学与寄生虫病杂志, 2018, 36(6): 636-642.
[6]	Cowman AF, Healer J, Marapana D, et al. Malaria: biology and disease[J]. Cell, 2016, 167(3): 610-624.
[7]	Goller JL, Jolley D, Ringwald P, et al. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy[J]. Am J Trop Med Hyg, 2007, 76(2): 203-207.
[8]	Sinden RE.Developing transmission-blocking strategies for malaria control[J]. PLoS Pathog, 2017, 13(7): e1006336.
[9]	Gatton ML, Chitnis N, Churcher T, et al. The importance of mosquito behavioural adaptations to malaria control in Africa[J]. Evolution, 2013, 67(4): 1218-1230.
[10]	Cao Y, Bansal GP, Merino K, et al. Immunological cross-reactivity between malaria vaccine target antigen P48/45 in Plasmodium vivax and P. falciparum and cross-boosting of immune responses[J]. PLoS One, 2016, 11(7): e0158212.
[11]	Marin-Mogollon C, van de Vegte-Bolmer M, van Gemert GJ, et al. The Plasmodium falciparum male gametocyte protein P230p, a paralog of P230, is vital for ookinete formation and mosquito transmission[J]. Sci Rep, 2018, 8(1): 14902.
[12]	Blagborough AM, Musiychuk K, Bi H, et al. Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax[J]. Vaccine, 2016, 34(28): 3252-3259.
[13]	Armistead JS, Morlais I, Mathias DK, et al. Antibodies to a single, conserved epitope in Anopheles APN1 inhibit universal transmission of Plasmodium falciparum and Plasmodium vivax malaria[J]. Infect Immun, 2014, 82(2): 818-829.
[14]	Draper SJ, Sack BK, King CR, et al. Malaria vaccines: recent advances and new horizons[J]. Cell Host Microbe, 2018, 24(1): 43-56.
[15]	Ecker A, Bushell ES, Tewari R, et al. Reverse genetics screen identifies six proteins important for malaria development in the mosquito[J]. Mol Microbiol, 2008, 70(1): 209-220.
[16]	李敏, 郑文琪, 何一雯, 等. 新型疟疾传播阻断疫苗候选抗原PbPSOP7基因截短片段的克隆及表达特点的研究[J]. 微生物学杂志, 2016, 36(4): 41-46.
[17]	Malkin EM, Durbin AP, Diemert DJ, et al. Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria[J]. Vaccine, 2005, 23(24): 3131-3138.
[18]	Sala KA, Nishiura H, Upton LM, et al. The Plasmodium berghei sexual stage antigen PSOP12 induces anti-malarial transmission blocking immunity both in vivo and in vitro[J]. Vaccine, 2015, 33(3): 437-445.
[19]	Zheng WQ, Kou X, Du YT, et al. Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei[J]. Vaccine, 2016, 34(23): 2570-2578.